Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Epigenetic de-repression of drivers of neuroendocrine prostate cancer [RNA-seq]

ABSTRACT: Epigenetic de-repression of drivers of neuroendocrine prostate cancer

ORGANISM(S): Homo sapiens

PROVIDER: GSE287183 | GEO | 2025/07/25

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Epigenetic de-repression of drivers of neuroendocrine prostate cancer [CUT&Run]

Project description:Epigenetic de-repression of drivers of neuroendocrine prostate cancer

2025-07-25 | GSE287182 | GEO

Neuroendocrine prostate cancer models

Project description:Neuroendocrine prostate cancer models

| PRJNA449097 | ENA

Epigenetic profiling of prostate adenocarcinoma and neuroendocrine prostate cancer models to understand EZH2 activity. [Cut & Run]

Project description:EZH2 has differential activity in prostate adenocarcinoma and neuroendocrine prostate cancer.

2024-07-16 | GSE256219 | GEO

Subtype Heterogeneity and Epigenetic Convergence in Neuroendocrine Prostate Cancer [ATAC-seq]

Project description:We analyzed chromatin accessibility, ChIP-seq and RNA-seq across neuroendocrine carcinomas from distinct anatomic origins including Merkel cell carcinomas, neuroendocrine prostate cancer, small cell lung cancer and gastrointestinal NECs.

2021-08-12 | GSE156291 | GEO

Subtype Heterogeneity and Epigenetic Convergence in Neuroendocrine Prostate Cancer [ChIP-seq]

2021-08-12 | GSE156290 | GEO

Subtype Heterogeneity and Epigenetic Convergence in Neuroendocrine Prostate Cancer [RNA-seq]

2021-08-12 | GSE156289 | GEO

Subtype Heterogeneity and Epigenetic Convergence in Neuroendocrine Prostate Cancer [scRNA-seq]

Project description:We analyzed chromatin accessibility, scATAC-seq and RNA-seq across neuroendocrine carcinomas from distinct anatomic origins including Merkel cell carcinomas, neuroendocrine prostate cancer, small cell lung cancer and gastrointestinal NECs.

2024-03-27 | GSE262624 | GEO

Subtype Heterogeneity and Epigenetic Convergence in Neuroendocrine Prostate Cancer [scATAC-seq]

2024-03-27 | GSE262623 | GEO

RET Kinase Inhibition in Neuroendocrine Prostate Cancer, part 2

Project description:Increased treatment of metastatic castration resistant prostate cancer (mCRPC) with second-generation anti-androgen therapies (ADT) has coincided with a greater incidence of lethal, aggressive variant prostate cancer (AVPC) tumors that have lost androgen receptor (AR) signaling. AVPC tumors may also express neuroendocrine markers, termed neuroendocrine prostate cancer (NEPC). Recent evidence suggests kinase signaling may be an important driver of NEPC. To identify targetable kinases in NEPC, we performed global phosphoproteomics comparing AR-negative to AR-positive prostate cancer cell lines and identified multiple altered signaling pathways, including enrichment of RET kinase activity in the AR-negative cell lines. Clinical NEPC and NEPC patient derived xenografts displayed upregulated RET transcript and RET pathway activity. Pharmacologically inhibiting RET kinase in NEPC models dramatically reduced tumor growth and cell viability in mouse and human NEPC models. Our results suggest that targeting RET in NEPC tumors with high RET expression may be a novel treatment option.

2020-05-29 | PXD012971 | Pride

RET Kinase Inhibition in Neuroendocrine Prostate Cancer, part 1

2020-05-29 | PXD012970 | Pride